Pacira BioSciences, Inc. Market Cap ($1.02 Billion)
Market Cap & Net Worth: Pacira BioSciences, Inc. (PCRX)
Pacira BioSciences, Inc. market cap. Pacira BioSciences, Inc. (NASDAQ:PCRX) has a market capitalization of $1.02 Billion ($1.02 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8470 globally and #2487 in its home market, demonstrating a 0.14% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pacira BioSciences, Inc.'s stock price $36.39 by its total outstanding shares 39347924 (39.35 Million). Also see PCRX cash generation efficiency for how efficiently the company converts equity into cash flow.
Pacira BioSciences, Inc. Market Cap History (2015–2026)
Pacira BioSciences, Inc. market cap history from 2015 to 2026. Data shows change from $3.02 Billion to $1.43 Billion (-1.10% CAGR). Check Pacira BioSciences, Inc. share price for real-time trading data and today's change.
Index Memberships
Pacira BioSciences, Inc. is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.04% | #244 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #924 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.06% | #141 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.56 Trillion | 0.10% | #459 of 602 |
Weight: Pacira BioSciences, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pacira BioSciences, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pacira BioSciences, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Pacira BioSciences, Inc. (PCRX) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.40x
Pacira BioSciences, Inc.'s market cap is 1.40 times its annual revenue
Latest Price to Earnings (P/E) Ratio
144.77x
Pacira BioSciences, Inc.'s market cap is 144.77 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.27 Billion | $276.37 Million | -$37.95 Million | 4.60x | N/A |
| 2017 | $1.80 Billion | $286.63 Million | -$42.61 Million | 6.27x | N/A |
| 2018 | $1.69 Billion | $337.28 Million | -$471.00K | 5.02x | N/A |
| 2019 | $1.78 Billion | $421.03 Million | -$11.02 Million | 4.23x | N/A |
| 2020 | $2.35 Billion | $429.65 Million | $145.52 Million | 5.48x | 16.18x |
| 2021 | $2.37 Billion | $541.53 Million | $41.98 Million | 4.37x | 56.40x |
| 2022 | $1.52 Billion | $666.82 Million | $15.91 Million | 2.28x | 95.49x |
| 2023 | $1.33 Billion | $674.98 Million | $41.95 Million | 1.97x | 31.64x |
| 2024 | $741.31 Million | $700.97 Million | -$99.56 Million | 1.06x | N/A |
| 2025 | $1.02 Billion | $726.41 Million | $7.03 Million | 1.40x | 144.77x |
Competitor Companies of PCRX by Market Capitalization
Companies near Pacira BioSciences, Inc. in the global market cap rankings as of November 1, 2026. Also see total assets of Pacira BioSciences, Inc. for a full breakdown of the balance sheet.
Key companies related to Pacira BioSciences, Inc. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Pacira BioSciences, Inc. (2015–2026)
Market capitalization of Pacira BioSciences, Inc. from 2015 to today. Between 2015 and today, Pacira BioSciences, Inc.'s market cap moved from $3.02 Billion to $ 1.43 Billion, with a yearly change of -1.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.43 Billion | +40.61% |
| 2025 | $1.02 Billion | +37.37% |
| 2024 | $741.31 Million | -44.16% |
| 2023 | $1.33 Billion | -12.61% |
| 2022 | $1.52 Billion | -35.83% |
| 2021 | $2.37 Billion | +0.55% |
| 2020 | $2.35 Billion | +32.10% |
| 2019 | $1.78 Billion | +5.30% |
| 2018 | $1.69 Billion | -5.76% |
| 2017 | $1.80 Billion | +41.33% |
| 2016 | $1.27 Billion | -57.94% |
| 2015 | $3.02 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Pacira BioSciences, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.02 Billion USD |
| MoneyControl | $1.02 Billion USD |
| MarketWatch | $1.02 Billion USD |
| marketcap.company | $1.02 Billion USD |
| Reuters | $1.02 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension ind… Read more